Zynerba Pharmaceuticals (ZYNE)

[dhbuzz]

What GW Pharmaceuticals PLC (NASDAQ:GWPH) has achieved with its cannabis-derived Epidiolex treatment for seizures underlines the latent potential of Zynerba. A positive data readout for Zynerba in any one of its many clinical trials can create serious momentum.
Zynerba is also looking at a big addressable market. If GW Pharma’s Epidiolex is aimed at 35,000 to 40,000 patients suffering rare epilepsies, Zygel is looking at double the market for just Fragile X syndrome and almost a million patients are diagnosed with autism.